Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
Trial Parameters
Brief Summary
The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases from non-small cell lung cancer (NSCLC). The main questions it aims to answer are: * Does Cadonilimab combined with SRT in the second-line treatment of brain metastases provide better results? * Is the toxicity of Cadonilimab combined with SRT manageable in second-line treatment of brain metastases? Researchers will compare evaluate the efficacy and safety of Cadonilimab combined with SRT as a second-line treatment for patients with advanced NSCLC： * Receive Cadonilimab combined with SRT for brain lesions. * Visit the hospital regularly once every 12 weeks for checkups and tests
Eligibility Criteria
Inclusion Criteria: 1. 18 years old ≤ 75 years old; Both male and female; 2. ECOG 0-1; 3. Histologically or cytologically confirmed non-small cell lung cancer; 4. Progression with brain metastasis after previous first-line anti-tumor therapy; 5. Requirements for brain metastases: ① measurable brain metastases without radiotherapy; ②SRS/FSRT: the maximum tumor volume of brain metastases was less than 10cm3, the single diameter was less than 3cm, and the total volume of brain metastases involved was less than 15 cm3. 6. Response to previous checkpoint inhibitor therapy on the initial response assessment; 7. If a metastatic lesion of the head has been irradiated, the cumulative radiation dose does not exceed the tolerated dose to all structures. 8. For patients with measurable CNS lesions, the longest diameter on MRI images is ≥10mm, which is suitable for repeated and accurate measurement. 9. Subjects were evaluated for all extracranial disease sites (e.g., by computed tomography (CT) sca